Koshinski Asset Management Inc. increased its stake in Pfizer Inc. (NYSE:PFE) by 19.3% in the second quarter, Holdings Channel.com reports. The institutional investor owned 28,430 shares of the biopharmaceutical company’s stock after purchasing an additional 4,609 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Pfizer were worth $930,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of PFE. Corbett Road Capital Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $25,000. New England Investment & Retirement Group Inc. acquired a new stake in shares of Pfizer in the first quarter valued at about $26,000. Lion Street Advisors LLC acquired a new stake in shares of Pfizer in the first quarter valued at about $27,000. Reitz Capital Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $29,000. Finally, Benjamin Edwards Inc. grew its stake in shares of Pfizer by 49.8% in the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 335 shares in the last quarter. Institutional investors and hedge funds own 70.20% of the company’s stock.
PFE has been the subject of a number of recent research reports. Piper Sandler increased their target price on Pfizer from $18.50 to $24.00 in a research note on Friday, June 26th. Mizuho restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Tuesday. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a research note on Monday, May 4th. JPMorgan Chase & Co. lowered their price objective on Pfizer from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Monday, June 1st. Finally, ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $38.95.
In related news, SVP Jennifer B. Damico sold 2,181 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $36.13, for a total value of $78,799.53. Following the sale, the senior vice president now owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.08% of the company’s stock.
NYSE:PFE opened at $38.48 on Friday. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56. The business’s 50 day moving average is $34.75 and its two-hundred day moving average is $35.79. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97. The company has a market cap of $213.75 billion, a PE ratio of 15.27, a P/E/G ratio of 3.12 and a beta of 0.68.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. Pfizer had a return on equity of 25.10% and a net margin of 28.80%. The company had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same quarter last year, the business posted $0.80 EPS. Pfizer’s quarterly revenue was down 11.0% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 31st will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.95%. The ex-dividend date is Thursday, July 30th. Pfizer’s dividend payout ratio (DPR) is 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Why is cost of goods sold important?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.